ArticleJournal of translational medicine2025
FAIM modulates HCC progression via enhancing HMGA1 interaction with CDK7 and promoting its phosphorylation level.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC), characterized by its aggressive trait and rapid progression, stands as one of the leading causes of cancer-related death worldwide. Fas apoptotic inhibitory molecule (FAIM), a death receptor antagonist, impedes cell apoptosis by reinforcing protein phosphorylation and stability. High mobility group A1 (HMGA1) is reported to be subject to multiple posttranslational modification, and plays a crucial role in HCC development. However, whether FAIM facilitates tumorigenesis through modulating HMGA1 phosphorylation remains unclear.
methodsWe applied Huh7 and SNU387 cells to investigate the regulatory role of FAIM in cell proliferation and apoptosis. Next, we constructed a male BALB/C mouse model with HCC to explore the biological function of FAIM in tumor growth. Subsequently, anti-FAIM proteomic and phosphorylation proteomic profiles were performed to screen HMGA1 as the FAIM-modulated downstream phosphorylated protein. Eventually, a series of immunoprecipitation (IP) tests and in vitro kinase assay revealed the crosstalk of FAIM, cyclin-dependent kinase7 (CDK7) and HMGA1, and unveiled the vital value of FAIM in HCC pathogenesis.
resultsIn vitro and in vivo experiments validated that FAIM overexpression was advantageous for HCC progression. Thereafter, anti-FAIM proteomic profile identified that FAIM interacted with CDK7 and HMGA1. Phosphorylation proteomic profile revealed that the Ser36 of HMGA1 was a downstream phosphorylation site of FAIM. Consistently, Co-IP and cycloheximide assays verified that FAIM enhanced HMGA1 phosphorylation and stability. More importantly, recovery experiments identified that silencing HMGA1 altered the regulatory role of overexpressed FAIM in Huh7 cells. Furthermore, we transduced Flag-HMGA1
conclusionsSummarily, we elucidated that FAIM modulated HCC progression through facilitating the interaction of CDK7 and HMGA1 as well as elevating HMGA1 phosphorylation and stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.